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Genetic variation of platelet glycoprotein VI and the
risk of venous thromboembolism
Family studies have indicated that heritability explains
50-60% of the venous thromboembolism (VTE) events,1
and in recent years, several single nucleotide polymor-
phisms (SNP) have been found to influence the VTE risk.2
Glycoprotein VI (GP6) rs1613662, also known as
T13254C, is an A/G single nucleotide variation in amino
acid 219, which results in a serine to proline substitution
affecting the glycoprotein VI (GPVI) receptor for
collagen.3 Platelets carrying the minor allele (G-
allele/Pro219) at GP6 rs1613662 express fewer GPVI
receptors,4 which leads to attenuated platelet adhesion
and activation.5 Previous observational studies in selected
populations have consistently demonstrated that carriers
of the A-allele at GP6 have a 15% higher risk of VTE than
non-carriers, and inversely, that G-allele carriers have a
20% lower VTE risk.6,7
Cancer is associated with a highly increased risk of
VTE,8 and the complex interactions between inherited
and acquired risk factors on VTE risk (e.g. genetic alter-
ations and platelet count) are more compound and often
different in malignancy.9,10 The impact of GP6 rs1613662
on the risk of VTE has only been investigated in case-
control studies, and the combined effect of GP6
rs1613662 and cancer on VTE risk has not been previ-
ously investigated. We therefore aimed (i) to investigate
the association between GP6 rs1613662 and VTE risk in
the general population and stratified by cancer status,
and (ii) to explore the combined effects of GP6 rs1613662
and active cancer on the risk of VTE, using a large case-
cohort recruited from the general population.
Cases with symptomatic, incident VTE (n=1,493) and a
subcohort (n=13,072) were recruited from the fourth sur-
vey of the Tromsø Study and the second survey of the
Nord-Trøndelag Health Study (HUNT), conducted in
1994-1995 and 1995-1997, respectively. Detailed descrip-
tions of both studies have been published previously.11,12
The Regional Committee of Medical Health Research
Ethics approved the studies, and all participants gave
their informed written consent to participate. VTE events
were identified by broad searches at the hospitals provid-
ing health care for the two regions and thoroughly vali-
dated by review of medical records, as previously
described in detail.13,14 We excluded participants not reg-
istered as inhabitants of Tromsø or Nord-Trøndelag at
study inclusion (n=3), subjects with a cancer diagnosis
prior to inclusion (n=573) or with missing values for GP6
rs1613662 (n=7). Eventually, the case-cohort consisted of
13,982 participants: 1,395 VTE cases and 12,587 subjects
in the subcohort. GP6 rs1613662 was genotyped with
the Sequenom platform as previously described else-
where.10 The HUNT study performed genotyping using
the Illumina HumanCore Exome array. Information
regarding date of cancer diagnosis, primary site of malig-
nancy (ICD-7-codes 140-205) and cancer stage during the
entire follow-up, was obtained by linkage to the Cancer
Registry of Norway.
Statistical analyses were performed using STATA ver-
sion 15.0 (Stata Corporation LP, College Station, TX,
USA). Cancer was entered as a time-varying covariate,
and the data was split in relation to the date of cancer
diagnosis.  A VTE were considered cancer-related if it
occurred within six months prior to and up to 2 years
after the date of cancer diagnosis. Subjects with cancer
who were alive and VTE-free at the end of the active can-
cer period were censored from this date onwards. Age-,
sex- and body mass index (BMI)-adjusted hazard ratios
(HR) with 95% confidence intervals (CI) for VTE were
calculated according to variants at GP6 rs1613662 sub-
jects with and without cancer. Subjects homozygous for
the major allele at GP6 (i.e. AA) were used as the refer-
ence group in the categorized analyses. The proportional
hazard assumption was confirmed by the use of
Schoeneld’s global test. The Fine–Gray model15 was
applied in a sensitivity analysis to account for mortality
as a competing event, and subdistribution hazard ratios
(SHR) were estimated. Mortality rates and HR for death
by categories of GP6 alleles were estimated for disease
free subjects, subjects with cancer only, subjects with
VTE only, and subjects with cancer-related VTE. The dis-
tribution of cancer sites and cancer stages were displayed
across GP6 variants (i.e. AA, AG and GG).
Baseline characteristics in the entire cohort and in sub-
jects with active cancer are presented in Table 1. The
allele frequency of GP6 was 0.17 in both the entire case-
cohort and in the active cancer group, which is similar to
the frequency reported in reference populations.2,3
Of the 1395 VTE events, 819 (58.7%) were deep vein
thrombosis (DVT) and 576 (41.3 %) were pulmonary
embolism (PE). The HR for VTE, DVT and PE adjusted
for age, sex and BMI by categories of GP6 alleles and can-
cer-status are presented in Table 2. The HR for incident
VTE was 21% (HR 0.79, 95% CI: 0.70-0.89) lower in
subjects with ≥1 G-alleles at GP6, when compared to
subjects homozygous for the A-allele. The VTE risk was
essentially similar for heterozygous (AG) and homozy-
gous (GG) subjects compared to those homozygous for
the major allele (AA). The number of G-alleles appeared
to have a differential effect on the risk of DVT and PE.
However, these findings should be interpreted with cau-
tion, as the number homozygous carriers in each catego-
ry was low. The mortality rates for the entire case-cohort
did not differ across the GP6 variants, and coherently, the
risk estimates from the competing risk by death model
were similar to those obtained with the traditional Cox
regression model (data not shown). 
In cancer-free subjects, the risk of incident VTE
decreased with the number of minor alleles, and subjects
homozygous for the GP6 allele (GG) had 34% decreased
risk of incident VTE (HR 0.66, 95% CI: 0.43-1.01) com-
pared to subjects homozygous for the major allele (A
allele) at GP6.
There were 1,536 patients with active cancer of which
233 (15.2%) experienced a VTE. Among cancer patients,
subjects heterozygous for the minor GP6 allele (AG)
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Table 1. Baseline characteristics of study participants.
                                            Entire Case-Cohort        Active Cancer
Subjects                                                     13,982                               1,536
Age (years)                                            51.2±16.5                        61.9±12.4
Sex (males)                                        47.4 (6,625)                     52.0 (800)
BMI (kg/m2)                                            26.3±4.2                          26.8±4.3
Daily smoking                                      29.4 (4,113)                     32.9 (505)
Self-reported CVD                              8.3 (1,161)                      12.6 (193)
GP6 rs1613662*                                           0.17                                  0.17
Heterozygous (AG)                                3,936                                  425
Homozygous (GG)                                   419                                    45
Values are numbers or percentages with numbers or means ± standard deviation
(SD) in parenthesis.  Active cancer: period from six months before a cancer diag-
nosis until 2 years after; BMI: body mass index; CVD: cardiovascular disease (stroke,
angina, myocardial infarction); *: allele frequency (G allele).
exhibited decreased VTE risk (HR 0.82, 95% CI: 0.60-
1.11), which was of similar magnitude to that found in
subjects without cancer. In contrast, cancer patients
homozygous for the G-allele had a higher risk of VTE,
DVT and PE, when compared to cancer patients
homozygous for the A-allele (AA). In cancer patients, the
risk of PE was particularly high in homozygous carriers of
the G-allele (HR 1.96, 95% CI: 0.78-4.94). 
The G-alleles were found to be associated with more
prothrombotic cancers (i.e. lung, colorectal, hematologi-
cal cancer and lymphomas) and presented with more
severe stages of cancer (i.e.distant metastasis), when
compared to subjects heterozygous or homozygous for
the A-allele (Table 3). To test whether the association
between homozygosity for the G-allele and increased
risk of cancer-related VTE could be explained by variant-
dependent differences in cancer types, cancer stages, and
mortality rates, additional adjustments of age, sex, BMI,
cancer types and stages as well as the Fine-Gray model
were applied (Table 2). When cancer types and stages
were included in the adjusted model, the risk estimates
were moderately attenuated. Moreover, the risk esti-
mates for cancer-related VTE in homozygous carriers of
the G-allele remained essentially unchanged when com-
peting risk by death was taken into account (data not
shown).
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Table 2. Hazard ratios with 95% confidence intervals for venous thromboembolism, deep vein thrombosis and pulmonary embolism by cat-
egories of GP6 rs1613662 alleles and cancer.
GP6                                                      All subjects                                       Cancer-free                                Active cancer
alleles                        Events              HR (95% CI)*               Events           HR (95% CI)*           Events         HR (95% CI)*            HR (95% CI)†
VTE                                                                                                                                                                                                                                                           
AA                                    1,039                            Ref.                               807                          Ref.                          168                        Ref.                                 Ref.
AG                                     321                    0.80 (0.70-0.89)                    242                0.77 (0.66-0.88)                55               0.82 (0.60-1.11)            0.84 (0.62-1.15)
GG                                      35                     0.83 (0.59-1.17)                     22                 0.66 (0.43-1.01)                10               1.61 (0.85-3.07)            1.39 (0.73-2.65)
AG/GG                                356                    0.79 (0.70-0.89)                    264                0.76 (0.66-0.87)                65               0.88 (0.66-1.18)            0.90 (0.67-1.20)
DVT                                                                                                                                                                                                                                                          
AA                                      593                              Ref.                               457                          Ref.                          102                        Ref.                                 Ref.
AG                                     209                    0.89 (0.76-1.05)                    158                0.88 (0.73-1.05)                37               0.91 (0.62-1.33)            0.95 (0.65-1.39)
GG                                      17                     0.70 (0.43-1.13)                     10                 0.52 (0.28-0.98)                 5                1.33 (0.54-3.28)            1.13 (0.46-2.79)
AG/GG                                226                    0.87 (0.75-1.02)                    168                0.84 (0.71-1.01)                42               0.94 (0.66-1.36)            0.97 (0.67-1.39)
PE                                                                                                                                                                                                                                                             
AA                                      446                              Ref.                               350                          Ref.                           66                         Ref.                                 Ref.
AG                                     112                    0.65 (0.53-0.80)                     84                 0.62 (0.49-0.79)                18               0.68 (0.41-1.16)            0.70 (0.41-1.18)
GG                                      18                     1.01 (0.63-1.62)                     12                 0.85 (0.48-1.50)                 5                1.96 (0.78-4.94)             1.69 (0.67-4.28
AG/GG                                130                    0.68 (0.56-0.83)                     96                 0.64 (0.51-0.80)                23               0.80 (0.50-1.29)            0.80 (0.50-1.30)
HR: hazard ratio; CI: confidence interval; *: adjusted for age, sex and body mass index (BMI); †: adjusted for age, sex, BMI, cancer site and cancer stage; Active cancer: period
from six months before a cancer diagnosis until two years after; Events: the number of venous thromboembolism (VTE), deep vein thrombosis (DVT), or pulmonary
embolism (PE) in each category. 
Table 3. The distribution of cancer types and stages across genotypes at GP6 rs1613662 alleles (AA, AG, GG).
Cancer site                                                AA (n=1,723)                      AG (n=702)                        GG (n=75)                     Total (n=2,500)
Colorectal                                                                283 (16.4)                                105 (15.0)                                14 (18.7)                                 402 (16.1)
Upper GI tract                                                           92 (5.3)                                    34 (4.8)                                     4 (5.3)                                    130 (5.2)
Pancreatic                                                                  53 (3.1)                                    15 (2.1)                                     2 (2.7)                                     70 (2.8)
Lung                                                                           178 (10.3)                                 85 (12.1)                                 15 (20.0)                                 278 (11.1)
Breast                                                                       176 (10.2)                                 86 (12.3)                                   2 (2.7)                                   264 (10.6)
Gynecologic                                                              102 (5.9)                                   45 (6.4)                                     1 (1.3)                                    148 (5.9)
Prostate                                                                    279 (16.2)                                119 (17.0)                                14 (18.7)                                 412 (16.5)
Urologic                                                                     155 (9.0)                                   57 (8.1)                                     6 (8.0)                                    218 (8.7)
CNS                                                                              67 (3.9)                                    33 (4.7)                                     1 (1.3)                                    101 (4.0)
Hematologic and lymph                                         154 (8.9)                                   45 (6.4)                                   9 (12.0)                                   208 (8.3)
Remaining cancers*                                              184 (19.7)                                 78 (11.1)                                   7 (9.3)                                   269 (10.8)
Cancer stage                                                                                                                                                                                                                            
Localized disease                                                   586 (34.0)                                277 (39.5)                                18 (24.0)                                 881 (35.2)
Regional spread                                                      399 (23.2)                                158 (22.5)                                17 (22.7)                                 574 (23.0)
Distant metastasis                                                 318 (15.5)                                126 (17.9)                                19 (25.3)                                 463 (18.5)
CNS: central nervous system; GI: gastrointestinal;*: ear, nose throat, melanomas, endocrine, sarcomas and unknown sites; N: indicates the number of cancers in each cate-
gory and the percentages are presented in parentheses.
Our findings support the notion that platelet function
is involved in the pathogenesis of VTE. The
mechanism(s) underlying the combined, but apparent
opposite effect of homozygosity at the G-allele of GP6
rs1613662 and cancer on VTE risk remains elusive. The
inverse effect may be explained by a differential impact
of the G-allele at GP6 rs1613662 on the cancer type, can-
cer stages and mortality rates. However, variants at the
GP6 rs1613662 may also have differential impact on
platelet reactivity under various conditions.
In contrast to cancer-free subjects where the VTE risk
decreased with the number of G-alleles, cancer patients
homozygous for the G-allele at GP6 rs1613662 displayed
an increased VTE risk.  Our findings imply that measures
of platelet function may have differential impact on the
VTE risk in cancer-free subjects and cancer patients.
Elevated platelet counts are frequently observed in cancer
patients, are associated with decreased survival,16 and
have been shown to predict future cancer-related VTE
events.9 In contrast, no association between platelet
count and the VTE risk has been observed in general pop-
ulations.9 In addition, mean platelet volume (MPV), a
marker of platelet reactivity, has shown differential asso-
ciation with VTE risk in subjects without and with can-
cer. Whereas high MPV is associated with an increased
risk of VTE in the general population,17 it is associated
with a lower VTE risk and improved survival in cancer
patients.18
The main strengths of our study are the prospective
design and the validation of VTE events and cancer diag-
noses. The high attendance rate and wide age distribu-
tion in the parent cohorts reduces the chance of selection
bias in the subcohort. Some limitations merit considera-
tion. Unfortunately, cancer treatment modality was not
available and restricted the possibility to evaluate the
relationship between treatment related factors and genet-
ics. Moreover, our study had limited statistical power,
particularly in some subgroups. This resulted in wide CI,
and our risk estimates should therefore be interpreted
with caution.
In conclusion, the GP6 rs1613662 G-allele displayed a
protective effect on VTE risk in cancer-free subjects,
while an increased risk of VTE was observed in cancer
patients homozygous for the G-allele. Our findings sup-
port a role of platelet reactivity in the pathogenesis of
VTE, which may differ according to cancer status.
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